Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 39.2% in April

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 1,040,000 shares, a drop of 39.2% from the March 31st total of 1,710,000 shares. Based on an average daily volume of 957,300 shares, the short-interest ratio is currently 1.1 days. Currently, 1.1% of the shares of the stock are sold short.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $0.65 on Tuesday. The stock has a market cap of $77.64 million, a price-to-earnings ratio of -0.67 and a beta of 2.15. The firm's 50-day simple moving average is $0.58 and its 200 day simple moving average is $0.60. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.29.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). On average, sell-side analysts predict that Unicycive Therapeutics will post -0.23 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Guggenheim started coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They issued a "buy" rating and a $6.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $7.50 price target on shares of Unicycive Therapeutics in a report on Friday, April 11th.

Institutional Investors Weigh In On Unicycive Therapeutics

Several large investors have recently bought and sold shares of UNCY. Virtu Financial LLC lifted its position in shares of Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after buying an additional 62,881 shares in the last quarter. Northern Trust Corp raised its stake in shares of Unicycive Therapeutics by 142.4% during the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after acquiring an additional 34,183 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Unicycive Therapeutics by 142.2% during the fourth quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after acquiring an additional 100,679 shares during the last quarter. Geode Capital Management LLC raised its stake in Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after acquiring an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC raised its holdings in shares of Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after purchasing an additional 323,801 shares during the last quarter. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.